BUNKER KEVIN D. (Chief Operating Officer) sold 6.7% of their position (10K shares) of ZENTALIS PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $490.7K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 3/21/2022ACC: 0001725160-22-000063
Officer· Chief Operating Officer
Since Apr 2020
-10K
Net shares
Net seller
$490.7K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
10K disposed
Non-Derivative Transactions2
Common Stock
Indirect
Shares
−5.56K
Price / share
$48.72
Trade value
$270.68K
% of position
3.7%
3/21/2022
150K→144.44K
Common Stock
Indirect
Shares
−4.44K
Price / share
$49.50
Trade value
$219.99K
% of position
3.1%
3/21/2022
144.44K→140K
Total
Net shares
−10K
Net value
-$490.67K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 3/21/2022 | S · Sale | −5.56K | $48.72 | $270.68K | 3.7% | 150K | 144.44K |
| Common Stock Indirect | 3/21/2022 | S · Sale | −4.44K | $49.50 | $219.99K | 3.1% | 144.44K | 140K |
| Total | −10K | -$490.67K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned350.00
Common Stock
DirectShares owned764.11K
Total
764.11K direct·350.00 indirect764.46K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 350.00 | Indirect |
| Common Stock | 764.11K | Direct |
| Total | 764.46K | 764.11K direct·350.00 indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported